For Healthcare Professionals

Expert Videos

Publication: CARMELINA Elderly Subgroup Analysis1

Review the long-term safety profile of Trajenta® among age groups.

See our infographic

Banner 2

Publication: CAROLINA Asian Subgroup Analysis2

Review the long-term safety profile of Trajenta® in Asian patients.

See our infographic

banner 3

Simple. Every Day.

When a DPP4i is needed, choose the Simplicity of Trajenta®.

banner 4

10 Years of Simplicity

Browse through an interactive infographic showcasing the clinical development and significant accomplishments for Trajenta®.

See the infographic

Trajenta®

(Linagliptin)

Trajenta - Expert videos

Expert Videos

Convenience

Not All DPP4i are the same-dosing & simplicity

Combination of Trajenta & Jardiance_0.png

What’s the first thing that comes to mind, when you hear the word “simplicity".png

is dpp4i suitable for admitted patients.png

whats next for dpp4i now that there are different agents out there is there still a role for dpp4i.png

Renal benefits

Evidences on renal safety microalbuminuria_0.png

Is Trajenta (linagliptin) contraindicated in renal failure.png

What are the evidence of Trajenta (Linagliptin) in patients with type 2 dia.png.png

Achieving optimal T2D management while considering potential future kidney function decline_0.png

Efficacy

Trajenta vs SU - Efficacy and safety.png

How has the type 2 diabetes landscape changed, before and after the availability of DPP4-inhibitors (2).jpg

Achieving optimal management in a patient with T2D and severe hyperglycemia.png

Safety

Guidelines

What are the evidences of Trajenta (linagliptin) in delaying the need for insulin among type 2 diabetes patients.png

Recent scientific data.png